The UK and US have agreed to a landmark trade agreement that will keep zero tariffs on British drug shipments entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the public health system. This commitment secures that tariffs on these vital products will remain at nothing for a duration of the next three years.
This agreement follows previous threats to dramatically increase tariffs on branded drug imports, with potential rates floated reaching 100%.
"This arrangement between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. drug exports," a release said.
Commercial Importance
Pharmaceuticals represent one of the Britain's biggest goods shipped to the US, which is by far the primary destination for large UK drugmakers.
Statistics show that in the year prior to the third quarter, the UK shipped pharmaceutical products totaling billions to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This guarantee safeguards employment, increases funding and facilitates the UK to establish itself as a worldwide center for life sciences," a government official remarked.
Key UK Commitments
The agreement includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Previously, repayments exceeded 20%.
Recent Tensions
The pact comes amid a ongoing tension between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were heightened by arguments that American customers were charged significantly more for the same drugs than people in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
A senior figure stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its total funding over the past decade.
